We studied the effects of Aeroxide P25 titanium dioxide nanoparticles (TiO2 NPs) with a diameter of 21 nm on induction of DNA damage and long-term survival of three human cell lines: hepatocellular liver carcinoma HepG2, colorectal adenocarcinoma HT29 and lung carcinoma A549. The endpoints examined were DNA breakage estimated by the comet assay and oxidative base damage recognized by formamide-pyrimidine glycosylase (FPG) estimated with the FPG+ comet assay, frequencies of histone γH2AX foci and micronuclei, apoptosis, cell metabolic activity measured by mitochondrial activity (MTT) assay and long-term survival measured by colony-forming ability. Each cell line had a different pattern of DNA breakage and base damage vs. nanoparticle (NP) concentration and treatment time. There was no increase in the frequencies of histone γH2AX foci and micronuclei as compared to those in the untreated cells. In parallel with these results, no induction of apoptosis has been found in none of the cell lines tested. The reported experiments provided no evidence of the long-term in vitro toxicity of Aeroxide P25 TiO2 NPs, despite a slight decrease in mitochondrial activity and cell survival during the first 72 h.
The Avrami–Dobrzyński (A–D) model interprets malignant transformation as a phase-transition-like process, mathematically equivalent to the Johnson–Mehl–Avrami–Kolmogorov equation from condensed-matter physics. In this framework, the cumulative probability of mutation burden among diagnosed patients is modelled with a Weibull-type sigmoidal function, interpreted as an approximation of the cumulative probability of neoplastic transformation, and, parametrized by a shape constant a and a critical scaling exponent k . Here, we test the generalizability of the A–D model by fitting its cumulative distribution function to clinical mutation-count data spanning 24 cancer types, and to analyse meaning of its parameters across a heterogeneous patient population. Mutation-count data for 70 studies (24 tumour types, n ⩾ 100 per study) were retrieved from cBioPortal. For each cohort, an empirical cumulative distribution P ( m ) was constructed from total non-synonymous mutation counts detected per sample. One-, two-, and three-component A–D mixture models (equivalent to Weibull mixture distributions) were fitted. Single-component A–D fits adequately described a minority of cohorts; the majority exhibited a characteristic ‘knee’ or wave-like inflection in the linearized representation, requiring two- or three-component mixture models. Depending on the model selection criterion used, the scaling exponent k varied widely across and fell below unity in 23%–26% of fitted components, indicating a decreasing-hazard regime. The k – a parameter space showed systematic co-variation with mean mutation burden. Superposition of decreasing- and increasing-hazard components within individual tumour categories generated composite hazard profiles, a pattern compatible with coexisting subpopulations with distinct transformation dynamics. The A–D model provides a physically grounded description of mutation-driven cancer transformation across diverse tumour types. Deviations from single-component behaviour are consistent with genuine biological heterogeneity within nominal tumour categories, although other factors for such deviation cannot be excluded. These findings support the broader applicability of phase-transition concepts in computational oncology and provide a quantitative framework for integrating genomic data into cancer risk modelling.